EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity

Toru Ishibashi, Hideki Tanioka, Tatsuya Ikehara, Safwan Kezbor, Takuhiro Sonoyama

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-024-01418-3 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Toru Ishibashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Project Management Department, Shionogi & Co., Ltd., 9F, Nissay Yodoyabashi East, 3-13, Imabashi 3-chome, Chuo-ku, Osaka, 541-0042, Japan. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi & Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAnti-Obesity AgentsHumansAdultMaleDouble-Blind MethodFemaleMiddle AgedYoung AdultDose-Response Relationship, DrugFood-Drug InteractionsAdministration, OralAdolescentHealthy VolunteersAcyltransferases

Substanzen

Anti-Obesity AgentsAcyltransferases

Autor:innen und Institutionen

  • Project Management Department, Shionogi & Co., Ltd., 9F, Nissay Yodoyabashi East, 3-13, Imabashi 3-chome, Chuo-ku, Osaka, 541-0042, Japan.
  • Project Management Department, Shionogi & Co., Ltd., 9F, Nissay Yodoyabashi East, 3-13, Imabashi 3-chome, Chuo-ku, Osaka, 541-0042, Japan. hideki.tanioka@shionogi.co.jp.
  • Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Clinical Development, Shionogi Inc., Florham Park, NJ, USA.
  • Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan.

Förderung

  • Shionogi & Co., Ltd.

Zitieren

APA

Ishibashi, T., Tanioka, H., Ikehara, T., Kezbor, S., & Sonoyama, T. (2025). Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01418-3

Vancouver

Ishibashi T, Tanioka H, Ikehara T, Kezbor S, Sonoyama T. Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity. Clinical Drug Investigation. 2025. doi:10.1007/s40261-024-01418-3

BibTeX
@article{Ishibashi2025,
  author = {Ishibashi, Toru and Tanioka, Hideki and Ikehara, Tatsuya and Kezbor, Safwan and Sonoyama, Takuhiro},
  title = {Safety, Tolerability, and Pharmacokinetics of a Novel Anti-obesity Agent, S-309309, in Healthy Adults with or Without Obesity},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-024-01418-3}
}
Kostenlos starten →